Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in children with moderate-to-severe atopic dermatitis
NCT06956196Phase 3Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Planned start May 2025; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06956196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956196.